Author: Chi Heem Wong; Kien Wei Siah; Andrew W Lo
Title: Estimating Probabilities of Success of Clinical Trials for Vaccines and Other Anti-Infective Therapeutics Document date: 2020_4_14
ID: fnrm6a79_40
Snippet: is the (which was not peer-reviewed) The copyright holder for this preprint It should be no surprise that investors are unwilling to invest in companies producing vaccines and treatments for infectious diseases given the economics of this market (Vu et al., 2020) . These have been generally regarded as low-margin products, and they have low growth potential compared to treatments in other therapeutic areas, such as oncology or cardiovascular dise.....
Document: is the (which was not peer-reviewed) The copyright holder for this preprint It should be no surprise that investors are unwilling to invest in companies producing vaccines and treatments for infectious diseases given the economics of this market (Vu et al., 2020) . These have been generally regarded as low-margin products, and they have low growth potential compared to treatments in other therapeutic areas, such as oncology or cardiovascular diseases. As a comparison, Revlimid, the blockbuster cancer drug for multiple myeloma, earned $9.69 billion for Celgene in 2019 (Celgene, 2019) , whereas the vaccine and antiviral portfolios of GlaxoSmithKline, the top vaccine producer by sales, generated only $6.65 billion and $5.89 billion in revenues, respectively, in 2017 (Evaluate, 2018).
Search related documents:
Co phrase search for related documents- cancer drug and cardiovascular oncology: 1, 2
- cancer drug and growth potential: 1
- cancer drug and infectious disease: 1, 2
- cancer drug and multiple myeloma: 1, 2
- cancer drug and multiple myeloma cancer drug: 1
- cancer drug and therapeutic area: 1
- cancer drug and treatment vaccine: 1, 2
Co phrase search for related documents, hyperlinks ordered by date